Author response for "A Randomized Phase III Study of Anlotinib Versus Bevacizumab in Combination With CAPEOX as First-Line Therapy for <i>RAS/BRAF</i> Wild-Type Metastatic Colorectal Cancer: A Clinical Trial Protocol"
crossref(2022)
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要